地舒单抗北京哪里有卖

Professor Niu Xiaohui, director of the Department of Bone Oncology at Beijing Jishuitan Hospital and chairman of the Sarcoma Expert Committee of the Chinese Society of Clinical Oncology, said: "According to a research report on the incidence of giant cell tumor of bone in China, the annual incidence of giant cell tumor of bone in China is estimated to be 1.49~2.57 Cases/1 million, current treatment methods mainly include surgery and radiotherapy. Surgery is the main treatment method for giant cell tumor of bone, but the postoperative recurrence rate is high. According to research, the recurrence rate of giant cell tumor of bone after curettage is 15% to 45%. It can control tumor growth to a certain extent, but there is a risk of post-radiotherapy complications and potential sarcomatous malignant transformation. For those patients who cannot be surgically resected or whose surgical resection will cause severe functional impairment, there are no effective treatments approved by Chinese regulatory authorities. The approval of denosumab means that the long-awaited innovative treatment option for giant cell tumor of bone in China has finally arrived. Its dual effects of inhibiting tumor growth and reducing bone destruction, as well as its good tolerability, will bring disease treatment benefits and improve the quality of life. "

Desosumab can significantly reduce tumor size, inhibit bone destruction and block pathological development. Since the reduction in size inhibits osteoclastosis and is accompanied by new bone formation, the tumor becomes smaller and the boundaries become clearer, making the surgical conditions that are inherently unresectable become resectable. In some special cases, denosumab can also be used for preoperative neoadjuvant treatment of giant cell tumor of bone. Clinical practice has proven that patients with giant cell tumors of bone can tolerate long-term treatment with denosumab very well, with fewer adverse reactions, minimal impact on neurological symptoms, and significant efficacy. Therefore, it is often used in class I recommendations for unresectable giant cell tumors of bone and class II recommendations for preoperative treatment. Currently, denosumab is available in all regions, and the price in China is ¥5298.00 unit/RMB. The price of denosumab in places such as India and Turkey is more affordable. It only costs more than 1,900 yuan when converted into RMB. However, it is not recommended to purchase it through purchasing agents. It is easy to be deceived into buying fake drugs. Those who have the conditions can go abroad to buy by themselves. Those who have no energy can also look for domestic overseas medical institutions for consultation and purchase.